Problem: Psoriasis is a TH17-mediated autoimmune disease of the skin. Clinical trials for treating severe psoriasis with anti-IL-17 or anti-IL-17-receptor blocking antibodies have shown promising results in the treatment of this chronic inflammatory disease. Which deleterious side effect is predicted to increase in frequency in patients given this treatment for 12 weeks? other autoimmune diseases, such as type 1 diabetes all viral infections in the treated individuals asthma attacks in patients with this allergy intracellular bacterial infections in the treated individuals upper respiratory infections in the treated individuals